NCT01886287View on ClinicalTrials.gov

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

October 31, 2014

Conditions
Neuroendocrine Carcinoma
Interventions
DRUG

Octreotide LAR

Octreotide LAR as outlined in Treatment Arm.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER